[go: up one dir, main page]

HUP0202424A3 - Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances containing benzazepine-n-acetic acid derivatives - Google Patents

Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances containing benzazepine-n-acetic acid derivatives

Info

Publication number
HUP0202424A3
HUP0202424A3 HU0202424A HUP0202424A HUP0202424A3 HU P0202424 A3 HUP0202424 A3 HU P0202424A3 HU 0202424 A HU0202424 A HU 0202424A HU P0202424 A HUP0202424 A HU P0202424A HU P0202424 A3 HUP0202424 A3 HU P0202424A3
Authority
HU
Hungary
Prior art keywords
medicament
acetic acid
acid derivatives
protective effect
substances
Prior art date
Application number
HU0202424A
Other languages
English (en)
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of HUP0202424A2 publication Critical patent/HUP0202424A2/hu
Publication of HUP0202424A3 publication Critical patent/HUP0202424A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0202424A 1999-07-13 2000-07-10 Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances containing benzazepine-n-acetic acid derivatives HUP0202424A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19932555A DE19932555A1 (de) 1999-07-13 1999-07-13 Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen

Publications (2)

Publication Number Publication Date
HUP0202424A2 HUP0202424A2 (hu) 2002-11-28
HUP0202424A3 true HUP0202424A3 (en) 2003-03-28

Family

ID=7914519

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202424A HUP0202424A3 (en) 1999-07-13 2000-07-10 Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances containing benzazepine-n-acetic acid derivatives

Country Status (28)

Country Link
US (1) US6906059B2 (hu)
EP (1) EP1200095B1 (hu)
JP (1) JP4824235B2 (hu)
KR (1) KR100738940B1 (hu)
CN (1) CN1267099C (hu)
AR (1) AR024476A1 (hu)
AT (1) ATE306926T1 (hu)
AU (1) AU782733B2 (hu)
BR (1) BR0012442A (hu)
CA (1) CA2377904C (hu)
CZ (1) CZ299070B6 (hu)
DE (2) DE19932555A1 (hu)
DK (1) DK1200095T3 (hu)
ES (1) ES2246874T3 (hu)
HK (1) HK1049116B (hu)
HU (1) HUP0202424A3 (hu)
IL (2) IL147604A0 (hu)
MX (1) MXPA02000411A (hu)
NO (1) NO329558B1 (hu)
NZ (1) NZ517130A (hu)
PL (1) PL198723B1 (hu)
RU (1) RU2268727C2 (hu)
SK (1) SK286020B6 (hu)
TR (1) TR200200053T2 (hu)
TW (1) TWI280880B (hu)
UA (1) UA73134C2 (hu)
WO (1) WO2001003699A1 (hu)
ZA (1) ZA200200265B (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
JP2004536063A (ja) * 2001-05-18 2004-12-02 ゾルファイ　ファーマスーティカルズ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング 医薬の製造における組み合わせたｎｅｐ／ｍｐ−抑制活性を有する化合物の使用
EP1448567B1 (en) * 2001-09-10 2009-12-30 Tibotec Pharmaceuticals Method for the preparation of hexahydro-furo 2,3-b furan-3-ol
CN100591689C (zh) * 2002-01-16 2010-02-24 索尔瓦药物有限公司 苯并氮杂环庚三烯化合物的固体盐及其在制备药物化合物中的应用
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
US7262184B2 (en) 2003-09-26 2007-08-28 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7452875B2 (en) 2003-09-26 2008-11-18 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7427611B2 (en) 2003-09-26 2008-09-23 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
JP4824573B2 (ja) 2003-11-18 2011-11-30 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 腎不全、腎疾患または腎障害、特に糖尿病患者におけるこれらの治療のための医薬組成物
US20050267124A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
US20050267072A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction
US20050288272A1 (en) * 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
EP1827448A1 (en) 2004-12-15 2007-09-05 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors
US20060205625A1 (en) * 2005-02-18 2006-09-14 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
NZ571465A (en) * 2006-02-27 2011-09-30 Targeted Molecular Diagnostics Llc Compositions and methods for reducing cellular fat and for predicting cardiac toxicity and upon treatment with tyrosine kinase inhibitors
WO2007102171A2 (en) * 2006-03-07 2007-09-13 Panacea Biotec Ltd Novel salts of 1h-1-benzazepine-1-acetic acid, their preparation and pharmaceutical composition
US20070292503A1 (en) * 2006-06-16 2007-12-20 Gorissen Henricus R Oral pharmaceutical composition of poorly water-soluble active substance
US20070299054A1 (en) * 2006-06-22 2007-12-27 Rajesh Jain Oral pharmaceutical composition of a poorly water-soluble active agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2850078A1 (de) * 1978-11-18 1980-05-29 Basf Ag Aminopropanolderivate des 6-hydroxy-2,3,4,5-tetrahydro-1h-1- benzazepin-2-ons
ES2198418T3 (es) * 1993-07-21 2004-02-01 Yamanouchi Pharmaceutical Co. Ltd. Derivado de la benzazepina de fusion y composicion farmaceutica que incluye este derivado.
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel
US6544979B1 (en) * 1997-09-18 2003-04-08 Janssen Pharmaceuticals, N.V. Fused imidazole derivatives for improving oral bioavailability of pharmaceutical agents
DE19906310A1 (de) * 1999-02-16 2000-08-17 Solvay Pharm Gmbh Arzneimittel zur Behandlung von Bluthochdruck
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen

Also Published As

Publication number Publication date
NO329558B1 (no) 2010-11-15
HK1049116B (zh) 2006-12-08
CA2377904A1 (en) 2001-01-18
ATE306926T1 (de) 2005-11-15
NO20020132L (no) 2002-03-12
SK142002A3 (en) 2002-06-04
EP1200095A1 (de) 2002-05-02
DE19932555A1 (de) 2001-01-18
IL147604A0 (en) 2002-08-14
DK1200095T3 (da) 2005-11-14
RU2268727C2 (ru) 2006-01-27
AU6157200A (en) 2001-01-30
IL147604A (en) 2006-12-31
NZ517130A (en) 2004-10-29
TR200200053T2 (tr) 2002-05-21
ES2246874T3 (es) 2006-03-01
NO20020132D0 (no) 2002-01-11
US20030040512A1 (en) 2003-02-27
TWI280880B (en) 2007-05-11
WO2001003699A1 (de) 2001-01-18
CN1373666A (zh) 2002-10-09
DE50011388D1 (de) 2006-03-02
SK286020B6 (sk) 2008-01-07
JP4824235B2 (ja) 2011-11-30
US6906059B2 (en) 2005-06-14
PL353012A1 (en) 2003-10-06
ZA200200265B (en) 2003-03-26
CN1267099C (zh) 2006-08-02
AU782733B2 (en) 2005-08-25
PL198723B1 (pl) 2008-07-31
UA73134C2 (en) 2005-06-15
CZ200252A3 (cs) 2002-08-14
AR024476A1 (es) 2002-10-02
MXPA02000411A (es) 2002-07-02
HUP0202424A2 (hu) 2002-11-28
KR100738940B1 (ko) 2007-07-12
JP2003504336A (ja) 2003-02-04
BR0012442A (pt) 2002-04-02
HK1049116A1 (en) 2003-05-02
CZ299070B6 (cs) 2008-04-16
KR20020019514A (ko) 2002-03-12
EP1200095B1 (de) 2005-10-19
CA2377904C (en) 2009-03-24

Similar Documents

Publication Publication Date Title
HUP0202424A3 (en) Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances containing benzazepine-n-acetic acid derivatives
AU5259100A (en) Medicament
HUP0105414A3 (en) Pyrrolo-isoquinoline, azepino- and diazepino-indole derivatives, their use and pharmaceutical compisitions containing them
AU2006601A (en) Medicament dispenser
AU2509901A (en) Medicament dispenser
HUP0104901A3 (en) Medicament dispenser
HUP0201633A2 (en) Alpha-aminosulphonyl-acetohydroxamic acid derivatives with metalloprotease inhibiting effect, preparation and use thereof
AU4136200A (en) Trigger safety
AU1514401A (en) Medicament dispenser
AU6923600A (en) Iv guard
AU6593600A (en) Drugs inhibiting cell death
GB9930079D0 (en) Medicaments
HUP0204360A3 (en) Substituted norbornylamino derivatives, method for the production thereof, use thereof as a medicament and medicaments containing said compounds
GB9930071D0 (en) Medicaments
AU1645700A (en) Oenothein medicaments
HUP0100939A3 (en) Spiropiperidine derivatives, medicaments containing them and their use
AU6987600A (en) Safety syringe
HUP0201810A3 (en) Sootepenseone and its derivatives, their preparation and use as medicament
AU4599500A (en) Safe
AU1752101A (en) Medicament cartridge
GB9924990D0 (en) Medicaments
GB9930083D0 (en) Medicaments
AU5557300A (en) Bafilomycin derivatives with anticancer activity
AU6073300A (en) N-heterocyclic derivatives with neuronal activity
GB9929040D0 (en) Medicaments

Legal Events

Date Code Title Description
FC4A Lapse of provisional application due to refusal